Treatment options for latent tuberculosis infection

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Treatment options for latent tuberculosis infection

Published Date:

November 2011

Source:

TB elimination

Language:

English

[PDF-195.72 KB]

Details:

Corporate Authors:

National Center for HIV, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.

Description:

Treatment of latent tuberculosis (TB) infection (LTBI) is essential to controlling and eliminating TB in the United States, because it substantially reduces the risk that TB infection will progress to TB disease. Certain groups are at very high risk of developing TB disease once infected. Once the diagnosis of LTBI has been made, health care providers must choose the most appropriate and effective treatment regimen, and make every effort to ensure those persons complete the entire course of treatment for LTBI. However, if exposed to and infected by a person with multidrug-resistant TB (MDR TB) or extensively drug-resistant TB (XDR TB), preventive treatment may not be an option.

Subject:

[+]

Document Type:

Pamphlet (or booklet)

Collection(s):

Stephen B. Thacker CDC Library collection

Main Document Checksum:

[+]

Supporting Files:

No Additional Files

No Related Documents.

You May Also Like:

Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020

Personal Author:

Sterling, Timothy R.; Njie, Gibril; Zenner, Dominik; Cohn, David L.; Reves, Randall; Ahmed, Amina; Menzies, Dick; Horsburgh, C. Robert; Crane, Charles M.; Burgos, Marcos; LoBue, Philip; Winston, Carla A.; Belknap, Robert;

Corporate Authors:

National Tuberculosis Controllers Association.. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination..

Published Date:

February 14 2020

Source:

MMWR Recomm Rep. 69(1):1-11

Description:

Comprehensive guidelines for treatment of latent tuberculosis infection (LTBI) among persons living in the United States were last published in 2000 (American Thoracic Society. CDC targeted tuberculin testing and treatment of latent tuberculosis infe...

Status:

current

File Type:

[PDF - 337.36 KB]
Risk Factors for and Trends in Isoniazid Monoresistance at Diagnosis of Tuberculosis—United States, 1993-2016

Personal Author:

Iqbal, Shareen A.; Armstrong, Lori R.; Kammerer, J. Steve; Truman, Benedict I.;

Published Date:

October 31 2019

Source:

J Public Health Manag Pract.

Description:

ContextResistance to isoniazid (INH) only (monoresistance), with drug susceptibility to rifampin, pyrazinamide, and ethambutol at diagnosis of tuberculosis (TB) disease, can increase the length of treatment.ObjectiveTo describe US trends in INH monor...

Public Access
Available on:

April 30, 2021
Patient information : the 12-dose regimen for latent tuberculosis (TB) infection

Corporate Authors:

National Center for HIV/AIDS, Viral Hepatis, STD, and TB Prevention (U.S.)

Published Date:

6/28/18

Description:

To treat your latent TB infection, take two medicines (rifapentine and isoniazid) once a week, for 12 weeks. It is important to take all of your medication. If you miss taking your pills for the week, call your doctor/clinic right away.CS292653Awww.c...

File Type:

[PDF - 150.71 KB]
Medication tracker : the 12-dose regimen for latent tuberculosis (TB) infection

Corporate Authors:

National Center for HIV/AIDS, Viral Hepatis, STD, and TB Prevention (U.S.)

Published Date:

6/21/18

Description:

CS292653BPublication date from document properties.LTBI_Medication_Tracker.pdf

File Type:

[PDF - 155.65 KB]
Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000–2015

Personal Author:

Loutet, Miranda G.; Davidson, Jennifer A.; Brown, Tim; Dedicoat, Martin; Thomas, H. Lucy; Lalor, Maeve K.;

Published Date:

Mar 2018

Source:

Emerg Infect Dis. 24(3):524-533.

Description:

Among tuberculosis (TB) patients, acquired resistance to anti-TB drugs represents a failure in the treatment pathway. To improve diagnosis and care for patients with drug-resistant TB, we examined the epidemiology and risk factors associated with acq...

File Type:

[PDF - 755.89 KB]